Jeffrey A. Jones

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text

Medicine, Hematology, Oncology +12

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd, Bonnie K. Harrington, Susan O’Brien et al. · New England Journal of Medicine · 2015 · 891 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan et al. · Blood · 2013 · 796 citations

Life Sciences, Immunology, Pharmacology +14

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

John C. Byrd, Richard R. Furman, Steven Coutré et al. · Blood · 2015 · 656 citations

Medicine, Pharmacology, Pharmacotherapy +8

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Kami J. Maddocks, Amy S. Ruppert, Gerard Lozanski et al. · JAMA Oncology · 2015 · 576 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16